Holen Sie sich die Stockscreener-App
3.94
5.07%
0.19
Handel nachbörslich:
3.94
Schlusskurs vom Vortag:
$3.75
Offen:
$3.77
24-Stunden-Volumen:
231.51K
Relative Volume:
0.39
Marktkapitalisierung:
$120.88M
Einnahmen:
$875.70K
Nettoeinkommen (Verlust:
$-39.57M
KGV:
-2.9353
EPS:
-1.3423
Netto-Cashflow:
$-33.65M
1W Leistung:
-3.19%
1M Leistung:
+10.99%
6M Leistung:
+68.38%
1J Leistung:
+27.92%
1-Tages-Spanne:
$3.7113
$3.97
1-Wochen-Bereich:
$3.69
$4.11
52-Wochen-Spanne:
$1.90
$4.52
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.94 | 115.05M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Should you hold or exit Vistagen Therapeutics Inc. nowWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Will breakout in Vistagen Therapeutics Inc. lead to full recoveryWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Vistagen Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Reactions & Intraday High Probability Setup Alerts - newser.com
Strategies to average down on Vistagen Therapeutics Inc.July 2025 Volume & Free Community Supported Trade Ideas - newser.com
Technical signs of recovery in Vistagen Therapeutics Inc.CPI Data & Community Consensus Stock Picks - newser.com
What dividend safety score for Vistagen Therapeutics Inc. stock2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Will Vistagen Therapeutics Inc. stock gain from strong economy2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Is Vistagen Therapeutics Inc. stock reversal real or fakeRecession Risk & Community Consensus Trade Signals - newser.com
Published on: 2025-11-01 04:45:37 - newser.com
Will Vistagen Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Technicals & Safe Capital Growth Plans - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.CEO Change & Reliable Price Action Trade Plans - newser.com
How to recover losses in Vistagen Therapeutics Inc. stockJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Vistagen Therapeutics Inc. a candidate for recovery playJuly 2025 Summary & Verified Momentum Watchlists - newser.com
Will Vistagen Therapeutics Inc. stock remain a Wall Street favoriteForecast Cut & Precise Buy Zone Identification - newser.com
Is Vistagen Therapeutics Inc. stock a safe haven assetTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
How to escape a deep drawdown in Vistagen Therapeutics Inc.Day Trade & Low Risk Investment Opportunities - newser.com
VistaGen Therapeutics Appoints Paul R. Edick to Board - The Globe and Mail
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer? - MSN
Can Vistagen Therapeutics Inc. stock deliver surprise earnings beatJuly 2025 Catalysts & Real-Time Market Trend Scan - newser.com
Published on: 2025-10-30 03:05:01 - newser.com
VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday - MarketBeat
Vistagen Therapeutics Appoints Paul R. Edick as Director - TradingView
Vistagen Appoints Paul Edick to Its Board of Directors, Audit Committee and the Compensation Committee - MarketScreener
Vistagen Appoints Paul Edick to its Board of Directors - Business Wire
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):